EpimAb Biotherapeutics to Showcase Innovations at SITC 2024

EpimAb Biotherapeutics' Exciting Journey at SITC 2024

SHANGHAI — EpimAb Biotherapeutics, a forefront player in biotechnology, specializes in the groundbreaking development of bispecific antibodies and T-cell engagers. The company is thrilled to announce their participation in the prestigious 39th Annual Meeting of the Society for Immunotherapy of Cancer, set to take place at the George R. Brown Convention Center in Houston, Texas. This significant event runs from November 6 to November 10, gathering experts from around the globe to share their insights and research.

Innovative Presentations to Watch

At this year's event, EpimAb will feature two poster presentations showcasing their cutting-edge work in cancer therapy:

Preclinical Results of cMet x EGFR Bispecific Antibody-Drug Conjugate

One of the highlighted presentations focuses on a novel cMet x EGFR bispecific antibody-drug conjugate (ADC). This ADC has demonstrated impressive antitumor activity across various preclinical models, coupled with a promising safety profile. The details of this presentation are as follows:

• Title: A differentiated cMet x EGFR bispecific antibody-drug conjugate demonstrated broad antitumor activity and promising safety profile in preclinical models
• Presentation Number: 1048
• Presentation Date: Saturday, November 9, 2024
• Viewing Time: Poster Viewing from 12:15 to 1:45 PM CST; Poster Reception from 7:10 to 8:30 PM CST (Exhibit Halls AB)

Advancements in NK Cell Engager Platform

The second presentation underlines the development of the IL15v-NKCE, an innovative NK cell engager platform poised to revolutionize cancer treatment. This advancement highlights the strides EpimAb is making in the domain of T-cell engagers:

• Title: The development of IL15v-NKCE: A cutting-edge NK cell engager platform for cancer treatment
• Presentation Number: 1078
• Presentation Date: Saturday, November 9, 2024
• Viewing Time: Poster Viewing from 12:15 to 1:45 PM CST; Poster Reception from 7:10 to 8:30 PM CST (Exhibit Halls AB)

About EpimAb Biotherapeutics

EpimAb Biotherapeutics is a clinical-stage biopharmaceutical enterprise dedicated to the creation of multispecific antibodies. The company's innovative FIT-Ig® and MAT-Fab bispecific platforms leverage extensive in-house research and technology capabilities. Through these advanced methods, EpimAb seeks to build a unique pipeline of transformative assets designed to spearhead change and improve outcomes for cancer patients worldwide.

Contact Information

For investors looking to learn more about EpimAb Biotherapeutics and its work, Dr. David Gu is available at +86-21-61951011. Additionally, inquiries can be directed to IR@epimab.com.

For business development questions, Dr. Jason Tang can be reached at +86-21-61951014, or at yesheng.tang@epimab.com.

Frequently Asked Questions

What is the focus of the presentations by EpimAb at SITC 2024?

The company will present their findings on bispecific antibody-drug conjugates and a novel NK cell engager platform aimed at cancer treatment.

When will EpimAb's presentations take place?

Both presentations are scheduled for Saturday, November 9, 2024, with specific viewing and reception times.

What does EpimAb Biotherapeutics specialize in?

EpimAb is focused on developing multispecific antibodies for innovative cancer therapies.

How can investors contact EpimAb's investor relations?

Investors can reach Dr. David Gu at +86-21-61951011 or via email at IR@epimab.com.

What are some of the benefits EpimAb aims to provide?

The company aims to create transformative assets that improve outcomes for patients suffering from cancer.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.